Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea

Suspended

• Conditions: CYP19; Aromatase Inhibitor; Polymorphism

• Registration Number: NCT01137136
• Lead Sponsor: Samsung Medical Center

Brief Summary

Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence of variation of CYP19 in Korea has not known. Therefore, the investigators want to know the incidence of variation of CYP19 and to assess the effect of these variations of CYP19 to aromatase inhibitor users.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06
• Study First Submitted: 2010-06-02
• Study First Submitted QC: 2010-06-03
• Study First Posted: 2010-06-04
• Status Verified: 2014-04
• Last Update Submitted: 2014-04-18
• Last Update Posted: 2014-04-21
• Primary Completion: 2014-12
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

• hormone receptor positiveBreast cancer patient
• postmenopausal women
• first user of aromatase inhibitor

Exclusion Criteria

• premenopausal
• The patient who take the other antihormonal therapy
• osteoporosis patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The prevalence of CYP19 polymorphism	12. 31. 2011

Secondary Outcome Measures

Name	Time	Method
The effect of CYP19 polymorphism to the prognosis of AI user	12. 31. 2016

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of